PET studies of functional compensation in a primate model of Parkinson's disease

NeuroReport

Volumn 8, Issue 12, 1997, Pages 2727-2733

  Eberling, J L ^a   Bankiewicz, K S ^a,b   Jordan, S ^a   VanBrocklin, H F ^a   Jagust, W J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CELL GENESYS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine; FMT; MPTP; Nigrostriata; Parkinson's disease; PET; Putamen; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; FLUORINE 18; GLIAL FIBRILLARY ACIDIC PROTEIN; LAMININ; PARGYLINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PERIKARYON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; SUBSTANTIA NIGRA;

EID: 0030875725     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199708180-00017     Document Type: Article

References (25)

1. Burns RS, Chiueh CC, Markey SP et al. Proc Natl Acad Sci USA 80, 4546-4550 (1983).
2. Davis GC, Williams AC, Markey SP et al. Psychiat Res 1, 249-254 (1979).
3. Langston JW, Ballard PA, Tetrud JW et al. Science 219, 979-980 (1983).
4. Bankiewicz KS, Oldield EH, Chiueh CC et al. Life Sci 39, 7-16 (1986).
5. Wienhard K, Dahlbom M, Eriksson L et al. J Comput Assist Tomogr 18, 110-118 (1994).
6. Jordan S, Eberling JL, Bankiewicz KS et al. Brain Res 750, 264-276 (1997).
7. Klein GJ, Teng X, Jagust WJ et al. IEEE Trans Med Imag (in press).
8. Cohen G, Pasik P, Cohen B et al. Eur J Pharm 106, 209-210 (1984).
9. Langston JW, Irwin I, Langston EB et al. Science 225, 1480-1482 (1984).
10. Elsworth JD, Deutch AV, Redmond DE Jr et al. Brain Res 513, 320-324 (1990).
11. Chiueh C, Burns R, Markey S et al. Life Sci 36, 213-218 (1985).
12. Elsworth JD, Deutch AY, Redmond DE Jr et al. Neuroscience 33, 323-331 (1989).
13. Greenwood CE, Tatton WG, Seniuk NA et al. Neurobiol Aging 12, 557-565 (1991).
14. Javitch JA, Strittmatter SM and Snyder SH. J Neurosci 5, 1513-1521 (1985).
15. Tipton KF and Singer TP. J Neumchem 61, 1191-1206 (1993).
16. Javitch JA, D'Amato RJ, Strittmatter SM et al. Proc Natl Acad Sci USA 82, 2173-2177 (1985).
17. Albanese A, Granata R, Gregori B et al. Neuroscience 55, 823-832 (1993).
18. Herkenham M, Little MD, Bankiewicz K et al. Neurosci 40, 133-158 (1991).
19. Jacobowitz DM, Burns RS, Chiueh CC et al. Psychopharmacol Bull 20, 416-422 (1984).
20. Imai H, Nakamura T, Endo K et al. Brain Res 474, 327-332 (1988).
21. Kitt CA, Cork LC, Eidelberg F et al. Neuroscience 17, 1089-1103 (1986).
22. Heikkila RE, Manzino L, Cabbat FS et al. Nature 311, 467-469 (1984)
23. Firnau G, Chirakal R, Nahmias C et al. J Label Comp Radiopharm 30, 272-273 (1991).
24. Melega WP, Perlmutter MM, Luxen A et al. J Neurochem 53, 311-314 (1989).
25. Nahmias C, Wahl L, Chirakal R et al. Movement Disorders 10, 298-304 (1995).